Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Ioannis K. Karalis, Sandrin C. Bergheanu, Ron Wolterbeek, Geesje M. Dallinga-Thie, Hiroaki Hattori, Arie van Tol, Anho H. Liem & J. Wouter Jukema. (2010) Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Current Medical Research and Opinion 26:10, pages 2301-2313.
Read now
Read now
Joe Gray, Steven J. Edwards & Gregory Y.H. Lip. (2010) Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials. Current Medical Research and Opinion 26:3, pages 537-547.
Read now
Read now
Sandrin C. Bergheanu, Theo Reijmers, Aeilko H. Zwinderman, Ivana Bobeldijk, Raymond Ramaker, An-Ho Liem, Jan van der Greef, Thomas Hankemeier & J. Wouter Jukema. (2008) Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Current Medical Research and Opinion 24:9, pages 2477-2487.
Read now
Read now
S. C. Bergheanu, A. Van Tol, G. M. Dallinga-Thie, A. Liem, P. H. J. Dunselman, J. G. Van Der Bom & J. W. Jukema. (2007) Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Current Medical Research and Opinion 23:9, pages 2235-2240.
Read now
Read now
Jaakko Tuomilehto. (2007) Rosuvastatin: The Most Efficient Treatment Option For Patients With Dyslipidemia. Future Lipidology 2:2, pages 127-141.
Read now
Read now
Jun-ren Zhu, Brian Tomlinson, Young Moo Ro, Kui-Hian Sim, Yuan-Teh Lee & Charn Sriratanasathavorn. (2007) A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Current Medical Research and Opinion 23:12, pages 3055-3068.
Read now
Read now
Haralampos J. Milionis, Evangelos Rizos, Michael Kostapanos, Theodosios D. Filippatos, Irene F. Gazi, Emmanuel S. Ganotakis, John Goudevenos, Dimitri P. Mikhailidis & Moses S. Elisaf. (2006) Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Current Medical Research and Opinion 22:6, pages 1123-1131.
Read now
Read now
Articles from other publishers (43)
Annisa Ayuningtyas, Kis Djamiatun, Tri Winarni Agustini & Luthfia Dewi. (2023) L. vannamei shells reduces atherogenic index of plasma: A preclinical study in diabetic rats. Mediterranean Journal of Nutrition and Metabolism, pages 1-11.
Crossref
Crossref
Barthelemy Maidadi, Fidèle Ntchapda, David Miaffo & Abba Talba Mahamad. (2023) Diabetes mellitus: Preventive and curative therapies with aqueous extract of Rytigynia senegalensis Blume (Rubiaceae) in Wistar rats. Journal of Traditional and Complementary Medicine 13:4, pages 358-367.
Crossref
Crossref
Myriam Jaam, Hend Nasser Al-Naimi, Moumena Mahmoud Haddad, Dina Abushanab & Daoud Al-Badriyeh. (2023) Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis. Journal of Comparative Effectiveness Research 12:3.
Crossref
Crossref
Eleonora Camilleri, Nienke van Rein, Bart J.M. van Vlijmen, Joseph S. Biedermann, Marieke J.H.A. Kruip, Frank W. Leebeek, Felix J. van der Meer, Christa M. Cobbaert, Suzanne C. Cannegieter & Willem M. Lijfering. (2023) Influence of rosuvastatin on apolipoproteins and coagulation factor levels: Results from the STAtin Reduce Thrombophilia trial. Research and Practice in Thrombosis and Haemostasis 7:2, pages 100063.
Crossref
Crossref
Neil Bryan Newman, Mohit S. Agarwal & Natalie A. Ridge. 2023. Translational Radiation Oncology. Translational Radiation Oncology
139
143
.
Xinjie Yang, Chongyang Wu, Weike Su & Jingbo Yu. (2022) Mechanochemical C−X/C−H Functionalization: An Alternative Strategic Access to Pharmaceuticals. European Journal of Organic Chemistry 2022:8.
Crossref
Crossref
Julian Torres-Jacome, Brian Sabino Ortiz-Fuentes, Daniela Bernabe-Sanchez, Benjamin Lopez-Silva, Myrian Velasco, Martha Lucia Ita-Amador & Alondra Albarado-Ibañez. (2022) Ventricular Dysfunction in Obese and Nonobese Rats with Metabolic Syndrome. Journal of Diabetes Research 2022, pages 1-10.
Crossref
Crossref
Rafaela Geraldo, Carla S. Santos, Elisabete Pinto & Marta W. Vasconcelos. (2022) Widening the Perspectives for Legume Consumption: The Case of Bioactive Non-nutrients. Frontiers in Plant Science 13.
Crossref
Crossref
Chiao-Chih Huang, Tzu-Ching Lin, Chiung-Hui Liu, Hao-Chun Hu, Szu-Yin Yu, Shu-Jing Wu, Ming-Hong Yen, Yi-Hong Tsai & Fang-Rong Chang. (2021) Lipid Metabolism and its Mechanism Triggered by Supercritical CO2 Extract of Adlay (Coix lacryma-jobi var. ma-yuen (Rom. Caill.) Stapf) Bran in High-Fat Diet Induced Hyperlipidemic Hamsters. Frontiers in Pharmacology 12.
Crossref
Crossref
Mengna Zheng, Han Yu, Yong Xue, Tong Yang, Qiufen Tu, Kaiqing Xiong, Daihua Deng, Lei Lu & Nan Huang. (2021) The protective effect of hydrogen-rich water on rats with type 2 diabetes mellitus. Molecular and Cellular Biochemistry 476:8, pages 3089-3097.
Crossref
Crossref
Ana Reis, Sara Rocha & Victor de Freitas. (2021) Going “Green” in the Prevention and Management of Atherothrombotic Diseases: The Role of Dietary Polyphenols. Journal of Clinical Medicine 10:7, pages 1490.
Crossref
Crossref
Mamatchi Melila, Rajaram Rajendran, Awaga Kwami Lumo, Ganeshkumar Arumugam, Mabozou Kpemissi, Agbere Sadikou, Gabriel Lazar & Kou’santa Amouzou. (2019) Cardiovascular dysfunction and oxidative stress following human contamination by fluoride along with environmental xenobiotics (Cd & Pb) in the phosphate treatment area of Togo, West Africa. Journal of Trace Elements in Medicine and Biology 56, pages 13-20.
Crossref
Crossref
Sandro Spiller, Matthias Blüher & Ralf Hoffmann. (2018) Plasma levels of free fatty acids correlate with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 20:11, pages 2661-2669.
Crossref
Crossref
Bo‑Mi Kim, Byoung Cho & Seon Jang. (2018) Anti-obesity effects of Diospyros�lotus leaf extract in mice with high-fat diet-induced obesity. International Journal of Molecular Medicine.
Crossref
Crossref
Mathijs C. Bodde, Paul Welsh, Sandrin C. Bergheanu, Willem M. Lijfering, Bart Mertens, An-Ho Liem, Arnoud van der Laarse, Naveed Sattar & J. Wouter Jukema. (2018) A Rapid (Differential) Effect of Rosuvastatin and Atorvastatin on High-Sensitivity Cardiac Troponin-I in Subjects With Stable Cardiovascular Disease. Clinical Pharmacology & Therapeutics 104:2, pages 311-316.
Crossref
Crossref
Huijuan Jing, Juan Li, Jianjun Zhang, Wenshuai Wang, Shangshang Li, Zhenzhen Ren, Zheng Gao, Xinling Song, Xiuxiu Wang & Le Jia. (2018) The antioxidative and anti-aging effects of acidic- and alkalic-extractable mycelium polysaccharides by Agrocybe aegerita (Brig.) Sing. International Journal of Biological Macromolecules 106, pages 1270-1278.
Crossref
Crossref
Roelof AJ. Smit, J. Wouter Jukema & Stella Trompet. (2017) Increasing HDL-C levels with medication. Current Opinion in Lipidology 28:4, pages 361-366.
Crossref
Crossref
C. J. H. M. Klemann, G. J. M. Martens, M. Sharma, M. B. Martens, O. Isacson, T. Gasser, J. E. Visser & G. Poelmans. (2017) Integrated molecular landscape of Parkinson’s disease. npj Parkinson's Disease 3:1.
Crossref
Crossref
Wen-Ching Huang, Che-Li Lin, Yi-Ju Hsu, Yen-Shuo Chiu, Yi-Ming Chen, Ming-Fang Wu, Chi-Chang Huang & Ming-Fu Wang. (2016) Inulin and Fibersol-2 Combined Have Hypolipidemic Effects on High Cholesterol Diet-Induced Hyperlipidemia in Hamsters. Molecules 21:3, pages 313.
Crossref
Crossref
Sunghwan SuhChang Hee JungSoon-Jun HongJung-Sun KimByung Ju SongHyun Soon SohnSung Hee Choi. (2016) Economic Evaluation of Rosuvastatin and Atorvastatin for the Treatment of Dyslipidemia from a Korean Health System Perspective. Journal of Lipid and Atherosclerosis 5:1, pages 61.
Crossref
Crossref
Chetan P. Shah, Dayanand K. Kumbla, Asha Moorthy, S. Murthy, Pankaj Aneja, Jagdish Gotur, Anil Gupta, Raman Abhi, Rajeev Bansal, Subhash Sonawala, Anil G. Balani, R. Kedarnathan, Pankaj Soni & P. Chinnaiyan. (2015) A post-marketing study evaluating the lipid-altering efficacy and safety of approved dose ranges of rosuvastatin in Indian hyperlipidemia patients in routine clinical practice (ROSUVEES). Journal of Indian College of Cardiology 5:4, pages 282-290.
Crossref
Crossref
Young Hee Choi, Jin Kyung Bae, Hee-Sung Chae, Young-Mi Kim, Yim Sreymom, Ling Han, Ha Young Jang & Young-Won Chin. (2015) α-Mangostin Regulates Hepatic Steatosis and Obesity through SirT1-AMPK and PPARγ Pathways in High-Fat Diet-Induced Obese Mice. Journal of Agricultural and Food Chemistry 63:38, pages 8399-8406.
Crossref
Crossref
Prisana Suwannaporn, Richard Frank Tester, Farage H. Al-Ghazzewi & Paponpat Artitdit. (2015) Effect of short term administration of konjac glucomannan hydrolysates on adult blood lipid parameters and glucose concentrations. Nutrition & Food Science 45:4, pages 616-624.
Crossref
Crossref
Stephen P Adams, Michael Tsang & James M Wright. (2015) Atorvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2017:1.
Crossref
Crossref
Zhi-Hua Lv, Pei Ma, Wan Luo, Hui Xiong, Lu Han, Si-Wei Li, Xin Zhou & Jian-Cheng Tu. (2014) Association between serum free fatty acid levels and possible related factors in patients with type 2 diabetes mellitus and acute myocardial infarction. BMC Cardiovascular Disorders 14:1.
Crossref
Crossref
Stephen P Adams, Sarpreet S Sekhon & James M Wright. (2014) Rosuvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2017:1.
Crossref
Crossref
Peter J. Meikle, Gerard Wong, Christopher K. Barlow & Bronwyn A. Kingwell. (2014) Lipidomics: Potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. Pharmacology & Therapeutics 143:1, pages 12-23.
Crossref
Crossref
Hisato Takagi, Masao Niwa, Yusuke Mizuno, Hirotaka Yamamoto, Shin-nosuke Goto & Takuya Umemoto. (2013) Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials. Heart and Vessels 29:3, pages 287-299.
Crossref
Crossref
Aliki A. Rasmiena, Theodore W. Ng & Peter J. Meikle. (2012) Metabolomics and ischaemic heart disease. Clinical Science 124:5, pages 289-306.
Crossref
Crossref
Stephen P Adams, Michael Tsang & James M Wright. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Paolo Sapienza, Valeria Borrelli, Antonio V. Sterpetti, Simona Dinicola, Elvira Tartaglia & Luca di Marzo. (2011) Dose-Dependent Effect of Rosuvastatin in the Regulation of Metalloproteinase Expression. Annals of Vascular Surgery 25:6, pages 823-829.
Crossref
Crossref
Paolo Sapienza, Valeria Borrelli, Antonio V. Sterpetti, Simona Dinicola, Elvira Tartaglia & Luca di Marzo. (2011) Effet dose-dépendant de la rosuvastatine sur la régulation de l'expression des métalloprotéinases. Annales de Chirurgie Vasculaire 25:6, pages 878-884.
Crossref
Crossref
T.-C. Weng, Y.-H. Kao Yang, S.-J. Lin & S.-H. Tai. (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. Journal of Clinical Pharmacy and Therapeutics 35:2, pages 139-151.
Crossref
Crossref
John Wlodarczyk, David Sullivan & Michael Smith. (2008) Comparison of Benefits and Risks of Rosuvastatin Versus Atorvastatin from a Meta-Analysis of Head-to-Head Randomized Controlled Trials. The American Journal of Cardiology 102:12, pages 1654-1662.
Crossref
Crossref
Hemanth Neeli & Daniel J. Rader. (2008) Cholesteryl Ester Transfer Protein (CETP) Inhibitors: Is There Life After Torcetrapib?. Cardiology Clinics 26:4, pages 537-546.
Crossref
Crossref
Willeke de Haan, Caroline C. van der Hoogt, Marit Westerterp, Menno Hoekstra, Geesje M. Dallinga-Thie, Hans M.G. Princen, Johannes A. Romijn, J. Wouter Jukema, Louis M. Havekes & Patrick C.N. Rensen. (2008) Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 197:1, pages 57-63.
Crossref
Crossref
Göran Walldius & Ingmar Jungner. (2007) Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Current Opinion in Cardiology 22:4, pages 359-367.
Crossref
Crossref
Mehmet Birhan Yilmaz. (2007) Statins and Aortic Stenosis in the Context of Ratio of Low- to High-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 50:3, pages 289-290.
Crossref
Crossref
Valmore Bermúdez-Pirela, Aida Souki, Clímaco Cano-Ponce, Fernando Bermúdez-Arias, Edgardo Mengual-Moreno, Elliuz Leal-Gonzalez, Miguel Lemus-Antepaz, Mayela Cabrera de Bravo, Anilsa Amell de Díaz, Nilka Leal de Pirela, Raquel Cano-Peñaloza, Guillermo Puche-Medina, Navlet Arraiz, Nadia Reyna-Villazmil, Freddy Contreras, Zafar H Israili & Manuel Valasco. (2007) Ciprofibrate Treatment Decreases Non-high Density Lipoprotein Cholesterol and Triglycerides and Increases High Density Lipoprotein Cholesterol in Patients With Frederickson Type IV Dyslipidemia Phenotype. American Journal of Therapeutics 14:2, pages 213-220.
Crossref
Crossref
Nadia Reyna-Villasmil, Valmore Bermúdez-Pirela, Edgardo Mengual-Moreno, Nelly Arias, Clímaco Cano-Ponce, Elliuz Leal-Gonzalez, Aida Souki, George E Inglett, Zafar H Israili, Rafael Hernández-Hernández, Manuel Valasco & Naikt Arraiz. (2007) Oat-derived β-Glucan Significantly Improves HDLC and Diminishes LDLC and Non-HDL Cholesterol in Overweight Individuals With Mild Hypercholesterolemia. American Journal of Therapeutics 14:2, pages 203-212.
Crossref
Crossref
James Shepherd, Donald G. Vidt, Elinor Miller, Susan Harris & James Blasetto. (2007) Safety of Rosuvastatin: Update on 16,876 Rosuvastatin-Treated Patients in a Multinational Clinical Trial Program. Cardiology 107:4, pages 433-443.
Crossref
Crossref
Charles J. Glueck, Dawit Aregawi, Mahlia Agloria, Qasim Khalil, Magdalena Winiarska, Jitender Munjal, Srikanth Gogineni & Ping Wang. (2006) Rosuvastatin 5 and 10 mg/d: A pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach ldl cholesterol goals with nonstatin lipid-lowering therapies. Clinical Therapeutics 28:6, pages 933-942.
Crossref
Crossref
G. WALLDIUS & I. JUNGNER. (2006) The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. Journal of Internal Medicine 259:5, pages 493-519.
Crossref
Crossref